Cancer Therapy News and Research

RSS
Succinate receptor can be a potential target for cancer treatment

Succinate receptor can be a potential target for cancer treatment

A class of FDA-approved drugs can effectively stop aggressive uterine cancer

A class of FDA-approved drugs can effectively stop aggressive uterine cancer

Scientists find better treatment options for patients with advanced colorectal cancer

Scientists find better treatment options for patients with advanced colorectal cancer

COVID-19 vaccines offer protection for multiple myeloma patients, but lesser than other cancer survivors

COVID-19 vaccines offer protection for multiple myeloma patients, but lesser than other cancer survivors

Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

NRG Oncology CC004 trial: Bupropion does not improve sexual desire for female cancer survivors

NRG Oncology CC004 trial: Bupropion does not improve sexual desire for female cancer survivors

Johns Hopkins astrophysicist receives Life Sciences 2021 award for novel cancer mapping technology

Johns Hopkins astrophysicist receives Life Sciences 2021 award for novel cancer mapping technology

COVID-19 vaccines shown to reduce SARS-CoV-2 infection rate in cancer patients

COVID-19 vaccines shown to reduce SARS-CoV-2 infection rate in cancer patients

Advancing our understanding of T cells to improve cancer therapies

Advancing our understanding of T cells to improve cancer therapies

Researchers identify new drug that makes pancreatic cancer cells more vulnerable to chemotherapy

Researchers identify new drug that makes pancreatic cancer cells more vulnerable to chemotherapy

Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System

Introducing the PhysioMimix™ OOC Multi-Organ Microphysiological System

Review highlights oncolytic viruses with remarkable ability to destroy cancer cells

Review highlights oncolytic viruses with remarkable ability to destroy cancer cells

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

Other molecules may have greater potential as cancer therapies than gold complex auranofin

Other molecules may have greater potential as cancer therapies than gold complex auranofin

UC researchers engineer new probiotic to target and break down cancer cell defenses

UC researchers engineer new probiotic to target and break down cancer cell defenses

Short-term severe calorie restriction safe, feasible, and well tolerated by cancer patients

Short-term severe calorie restriction safe, feasible, and well tolerated by cancer patients

Young adults with cancer may require different treatments than older patients

Young adults with cancer may require different treatments than older patients

Machine learning analysis of long non-coding RNAs reveals new prognostic cancer biomarkers

Machine learning analysis of long non-coding RNAs reveals new prognostic cancer biomarkers

Drug combination highly effective in children with standard- and high-risk acute promyelocytic leukemia

Drug combination highly effective in children with standard- and high-risk acute promyelocytic leukemia

Inhibiting epigenetic modification could be key to reducing cancer metastasis

Inhibiting epigenetic modification could be key to reducing cancer metastasis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.